*<unk>  is used in moderate-to-severe persistent asthma following previous treatment with a short-acting β2 adrenoreceptor agonist (SABA) such as salbutamol (albuterol). * LABAs should not be used as a monotherapy, instead, they should be used concurrently with an inhaled corticosteroid, such as beclometasone dipropionate or fluticasone propionate in the treatment of asthma to minimize serious reactions such as asthma-related deaths. Combination of inhaled corticosteroids and<unk>  (LABA) has synergistic action and reduces the frequency of asthma attacks and also makes it less severe. * In chronic obstructive pulmonary disease (COPD), LABAs may be used as monotherapy or in combination with corticosteroids. The Torch study demonstrated benefits in terms of quality of life and lung function of<unk>  alone or in combination with inhaled corticosteroids in patients with COPD * In exercise-induced bronchospasm monotherapy may be indicated in patients without persistent asthma. LABAs should not be used to treat acute symptoms. Pregnancy and lactation<unk>  use during pregnancy must be decided based on the risks versus benefits to the mother. There are no well-controlled studies with<unk>  in pregnant women. Some animal studies showed developmental malformation when the mother was given several clinical doses orally. In rats,<unk>  xinafoate is excreted in the milk. However, since there is no data to show excretion of<unk>  in a mother's breast milk, a decision on whether to continue or discontinue therapy should be decided based on the important benefits it provides to the mother. Pregnant and lactating women should consult their doctors before using<unk> .
Salmeterol
Fluticasone
Formoterol
Flumetasone
Arformoterol
Clobetasone
Levosalbutamol
Fluticasone propionate